Proteomics Sponsored by Bio-Rad
New open-access toolkit helps research labs study SARS-CoV-2
One of the most important factors in fighting the COVID-19 pandemic is large-scale scientific collaborations and knowledge sharing. One international group of researchers has made its simple, robust toolkit available to laboratories around the globe that are unaccustomed to working with coronaviruses. The details can be found in a PLOS Biology paper published on February 25. Read More
Automated flow cytometry can expedite the discovery and development of next-gen drugs
Automated flow cytometry workflows outperform manual gated techniques by reducing variability among samples, while still achieving a high degree of accuracy. Automated workflows offer a number of advantages to pharmaceutical companies that can integrate them to accelerate drug discovery and development. Read More
AI uncovers the genome's hidden regulatory code
A neural network trained on high-resolution maps of protein-DNA interactions can uncover how these sequences are organized to regulate genes, revealing a hidden regulatory code. Findings from use of the artificial intelligence (AI) model were published in Nature Genetics on February 18. Read More
mRNA vaccines are successful for COVID-19. But what about cancer?
Advances in platform technology for the development of messenger RNA (mRNA) vaccines have led to the authorization of several COVID-19 vaccines. But scientists are also working on developing mRNA vaccines to protect against or treat other diseases, such as cancer. This includes a hydrogel-based RNA vaccine, the design of which is discussed in an article published in Nano Letters on February 1. Read More
Researchers use modified CRISPR tool to manipulate the epigenome
Bioengineers have developed a new way to engineer the human epigenome (chemical changes in the DNA) using a modified CRISPR-Cas9 system to target and activate proteins in the chromosome. This research, published in Nature Communications on February 9, expands on synthetic genome tools. Read More
Recurrent deletions help SARS-CoV-2 mutate to escape antibodies
Researchers have identified a pattern of deletions in the spike glycoprotein of the SARS-CoV-2 virus that can prevent antibody binding, which is part of the body's immune response to a foreign virus. These deletions occur as a recurring pattern of evolution, according to a study published in Science on February 3. Read More
Acute SARS-CoV-2 infection elicits distinct antibody, T-cell responses
An analysis of antibody and T-cell responses during the entire timeline of SARS-CoV-2 infection reveals the different ways the immune system responds to the virus in the early phases of COVID-19 disease. The results, published in Cell Reports on January 21, suggest that T-cell responses may be important for controlling infection while antibodies provide longer protection. Read More
2003 SARS-CoV antibodies may provide some protection from SARS-CoV-2
A new study shows that antibodies against the original 2003 SARS-CoV also react with the current SARS-CoV-2 strain, but only with limited effectiveness. The findings were published in Cell Reports on January 25. Read More
New universal flu vaccine targets conserved region of viral surface protein
A new universal influenza vaccine has been developed that targets the stalk portion of the influenza virus surface protein rather than the head portion. This vaccine, which is capable of neutralizing diverse strains of influenza, was evaluated in a phase I clinical study whose results were published in Nature Medicine on December 7. Read More
Metabolic control of Tregs is critical for immune tolerance
A new study identifies how metabolism exerts control over regulatory T (Treg) cells, which play a key role in the recognition of foreign and self-produced molecules. The findings, published in Cell Metabolism on November 17, may help scientists identify new drug targets for autoimmune diseases and cancers. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter